Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients

European Journal of Neurology

Volumn 19, Issue 10, 2012, Pages 1311-1317

  Jensen, P E H ^a   Sellebjerg, F ^a   Sondergaard H B ^a   Sorensen P S ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Antibodies; ELISA; Interferon beta; Luciferase; Multiple sclerosis; MxA; Neutralizing; RT PCR

Indexed keywords

BETA1A INTERFERON; BINDING ANTIBODY; INTERFERON ANTIBODY; INTERFERON BETA SERINE; LUCIFERASE; MESSENGER RNA; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MX1 GENE; PRIORITY JOURNAL; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 85027953762     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03721.x     Document Type: Article

References (39)

1. Pestka S, Karuse CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8-32.
2. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-1191.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
4. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial Neurology 1995; 45: 1277-1285.
5. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
6. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
7. Fernandez O, Mayorga C, Luque G, et al. Study of binding and neutralizing antibodies to interferon-b in two groups of relapsing-remitting multiple sclerosis patients. J Neurol 2001; 248: 383-388.
8. Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-b antibody measurement in multiple sclerosis: report of an EFSN Task Force on IFN-b antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-827.
9. Koch-Henriksen N, Sorensen P, Bendtzen K, Flachs E. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Mult Scler J 2009; 15: 601-605.
10. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475.
11. van Beers MMC, Jiskoot W, Schellekens H. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res 2010; 30: 767-775.
12. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1 0401 and HLA-DRB1 0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008; 83: 219-227.
13. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
14. Gneiss C, Reindl M, Lutterotte A, et al. Interferon-beta: the neutralizing antibody (Nab) titres predicts reversion to Nab negativity. Mult Scler J 2004; 10: 507-510.
15. Farrell R, Kapoor R, Leary S, et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult Scler J 2008; 14: 212-218.
16. Sorensen PS. Neutralizing antibodies against interferon-beta. Ther Adv Neurol Dis 2008; 1: 62-78.
17. Sorensen PS, Koch-Henriksen N, Flachs E, Bendtzen K. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies? Mult Scler J 2008; 14: 837-842.
18. Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS-patients. Neurology 2003; 61: 1444-1446.
19. Hartung HP, Polman C, Bertolotto A, et al. Neutralising antibodies to interferon b in multiple sclerosis. Expert panel report. J Neurol 2007; 254: 827-837.
20. Deisenhammer F, Schellekens H, Bertolotto A. Measurements of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J Neurol 2004; 251(Suppl. 2): II/31-II/39.
21. Bendtzen K. Critical Review: assessment of Interferon-b Immunogenicity on Multiple Sclerosis. J Interferon Cytokine Res 2010; 30: 759-766.
22. Koch-Henriksen N, Sorensen PS. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. Multiple Sclerosis 2000; 6: 172-175.
23. Brickelmaier M, Hochman PS, Baciu R, Chao B, Cuervo JH, Whitty A. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta. J Immunol Methods 1999; 227: 121-135.
24. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003; 60: 634-639.
25. Pachner AR, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon-b bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003; 7: 17-25.
26. Sellebjerg F, Krakauer M, Hesse D, et al. Identification of new sensitive biomarkers for the in vivo response to interferon-β treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol 2009; 16: 1291-1298.
27. Pachner AR, Warth JD, Pace A, Goelz S. Effect of neutralizing antibodies on biomarker responses to interferon beta. The INSIGHT study. Neurology 2009; 73: 1493-1500.
28. Sorensen PS, Tscherning T, Mathiesen HK, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006; 67: 1681-1683.
29. Foote J, Milstein C. Kinetic maturation of an immune response. Nature 1991; 352: 530-532.
30. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999; 52: 1277-1279.
31. Ross C, Clemmensen KM, Sorensen PS, Koch-Henriksen N, Bendtzen K. Measuring and evaluating interferon-beta-induced antibodies in patients with multiple sclerosis. Mult Scler J 2006; 12: 39-46.
32. Pozzilli C, Antonini G, Bagnato F, et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 2002; 249: 50-56.
33. Hartung HP, Munschauer F, Schellekens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consus Conference. Eur J Neurol 2005; 12: 588-601.
34. Pachner AR, Narayan K, Pak E. Multiplex analysis of expression of three IFNb-induced genes in antibody-positive MS patients. Neurology 2006; 66: 444-446.
35. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740-750.
36. Lam R, Farrell R, Aziz T, et al. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods 2008; 336: 113-118.
37. Pungor E Jr, Files JG, Gabe JD, et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 1998; 18: 1025-1030.
38. Prince HE, Lapé-Nixon M, Audette C, et al. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera. J Neuroimmunol 2007; 190: 165-169.
39. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.